Skip to main content

Table 1 PDLSVT subject profiles. Levodopa equivalent values (LED) values represent the milligram dosage in each medication consumption

From: Quantitative clinical assessment of motor function during and following LSVT-BIG® therapy

Subject No. Age Gender Height Weight BMI Time Since Diagnosis Side Most Affected LED HY MDS-UPDRS Total MDS-UPDRS Motor PDQ39 ACE III PAS
[#] [yrs]   [m] [Kg] [Kg/m2] [yrs]   [mg] (Baseline) (Baseline) (Baseline) (Baseline) (Baseline) (Baseline)
1 78 M 1.72 80 26.98 0.5 Right 1003 3 58 37 27.56% 79% 8.33%
2 74 M 1.85 123.4 35.89 3.0 Left 1003 3 78 42 12.18% 94% 8.33%
3 66 M 1.75 76 24.74 8.0 Right 1504 2.5 67 33 26.92% 94% 27.08%
4 76 F 1.65 70.1 25.72 3.2 Right 1003 3 40 23 25.00% 96% 16.66%
5 67 M 1.73 72.8 24.25 2.0 Right 1003 2 29 9 21.15% 88% 20.83%
6 86 M 1.70 79.1 27.52 0.4 Right 62.52 1.5 16 11 12.82% 88% 6.25%
7 72 F 1.55 67.7 28.20 0.3 Right 12.53 1 9 5 11.54% 88% 18.75%
8 72 M 1.82 80.9 24.36 10.0 Left 1004, 200N 1.5 41 21 22.44% 83% 4.12%
9 75 F 1.57 66.2 26.69 0.4 Right 62.53 2.5 49 32 12.17% 78% 8.33%
10 84 M 1.80 68.5 21.06 4.0 Left 2602* 2.5 38 30 0.00% 87% 0.00%
11 72 M 1.73 74.8 25.07 3.0 Right 0 2.5 65 36 21.13% 87% 41.66%
12 75 M 1.71 109.4 37.49 0.7 Left 1503 1.5 35 18 10.26% 90% 25.00%
Mean 74.75   1.72 80.74 27.33 2.96    2.21 43.75 24.75 16.93% 87.67% 15.45%
(SD) 5.91   0.09 17.61 4.77 3.14    0.69 20.72 12.11 0.08 0.06 0.12
  1. 2 - BDS, 3 - TDS, 4 - QDS, N - Nocte, * - Controlled Release form
  2. [HY = Hoehn Yahr; MDS-UPDRS = Movement-Disorder-Society Unified-Parkinson’s-Disease-Rating-Scale; PDQ39 = Parkinson’s Disease Questionnaire 39; ACE III = Addenbrooke’s Cognitive Examination; PAS = Parkinson’s Anxiety Scale]